Trial reportProceedings of the National Academy of Sciences of the United States of America2008
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 155 citations in OpenAlex.
- A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.Cancer immunology, immunotherapy : CII · 2016Trial
- Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2013Trial
- Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.Cancer immunology, immunotherapy : CII · 2011Trial
- NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Trial
- Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.Journal of immunology (Baltimore, Md. : 1950) · 2008Trial
- MAGEA Family Gene Expression Influences Survival in Intestinal-Type Gastric Cancer.Cancer medicine · 2026Article
- Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions.Oncology research · 2025Review
- Vaccination strategies, the power of the unmatched double hits.Future science OA · 2023Article
- Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer.Theranostics · 2023Article
- Immunological Effects of Dimethyldioctadecylammonium Bromide and Saponin as Adjuvants for Outer Membrane Vesicles fromDiseases (Basel, Switzerland) · 2022Article
- Development of Pharmaceutical Nanomedicines: From the Bench to the Market.Pharmaceutics · 2022Review
- T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors.Journal of hematology & oncology · 2021Review
- Antitumor effects of iPSC-based cancer vaccine in pancreatic cancer.Stem cell reports · 2021Article
- Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine.Stem cell reviews and reports · 2020Review
- Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire.Nature reviews. Clinical oncology · 2020Review
- Expression of tumor-associated antigens in breast cancer subtypes.Breast (Edinburgh, Scotland) · 2020Article
- Functional and mechanistic studies reveal MAGEA3 as a pro-survival factor in pancreatic cancer cells.Journal of experimental & clinical cancer research : CR · 2019Article
- Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression.Cancer science · 2019Article
- AttenuatedCancer biology & medicine · 2019Article
- High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.Molecular medicine reports · 2019Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously reported results of a phase II trial in which recombinant MAGE-A3 protein was administered with or without adjuvant AS02B to 18 non-small-cell lung cancer (NSCLC) patients after tumor resection. We found that the presence of adjuvant was essential for the development of humoral and cellular responses against selected MAGE-A3 epitopes. In our current study, 14 patients that still had no evidence of disease up to 3 years after vaccination with MAGE-A3 protein with or without adjuvant received an additional four doses of MAGE-A3 protein with adjuvant AS02B. After just one boost injection, six of seven patients originally vaccinated with MAGE-A3 protein plus adjuvant reached again their peak antibody titers against MAGE-A3 attained during the first vaccination. All seven patients subsequently developed even stronger antibody responses. Furthermore, booster vaccination widened the spectrum of CD4(+) and CD8(+) T cells against various new and known MAGE-A3 epitopes. In contrast, only two of seven patients originally vaccinated with MAGE-A3 protein alone developed high-titer antibodies to MAGE-A3, and all these patients showed very limited CD4(+) and no CD8(+) T cell reactivity, despite now receiving antigen in the presence of adjuvant. Our results underscore the importance of appropriate antigen priming using an adjuvant for generating persistent B and T cell memory and allowing typical booster responses with reimmunization. In contrast, absence of adjuvant at priming compromises further immunization attempts. These data provide an immunological rationale for vaccine design in light of recently reported favorable clinical responses in NSCLC patients after vaccination with MAGE-A3 protein plus adjuvant AS02B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.